Hematologic Malignancy
T-Cell and NK-Cell Neoplasm
CI-CAN-00001561Explore in graph →
HematologicNon-malignant268 active trials13 approved drugs18 evidence items
- NCIt
- C27908
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00001561Explore in graph →
Clinical trials
1,103 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05833893 | Clinical Study of XPO1 Inhibitor Selinexor Combined With COPL in Newly Diagnosed Advanced NK/T-cell Lymphoma | recruiting | Phase 2 | 10 | Chinese PLA General HospitalOTHER | 1 | Apr 27, 2023 | clinicaltrials |
| NCT04526834 | Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin Lymphoma(CERTAIN) | active not recruiting | Phase 1 | 21 | Tessa TherapeuticsINDUSTRY | 1 | Apr 20, 2023 | clinicaltrials |
| NCT05821192 | Chemotherapy Plus PD-1 Monoclonal Antibody in the Treatment of Refractory or Relapsed Peripheral T-cell Lymphoma. | unknown | N/A | 34 | Ou Bai, MD/PHDOTHER | 1 | Apr 20, 2023 | clinicaltrials |
| NCT02890368 | Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides | terminated | Phase 1 | 56 | PfizerINDUSTRY | 1 | Apr 5, 2023 | clinicaltrials |
| NCT02546440 | Study on Therapy With Dimethylfumarate (DMF) in Patients With Cutaneous T Cell Lymphoma (CTCL)(DMF-CTCL) | completed | Phase 2 | 25 | Universitätsmedizin MannheimOTHER | 1 | Mar 31, 2023 | clinicaltrials |
| NCT05131438 | An Expanded Access Program to Provide Sugemalimab for the Treatment of Relapsed or Refractory Extranodal Natural Killer/T-Cell Lymphoma (R/R ENKTL) | no longer available | — | — | EQRx International, Inc.INDUSTRY | 1 | Mar 27, 2023 | clinicaltrials |
| NCT00001582 | Investigation of the Human Immune Response in Normal Subjects and Patients With Disorders of the Immune System and Cancer | completed | — | 902 | National Cancer Institute (NCI)NIH | 1 | Mar 21, 2023 | clinicaltrials |
| NCT05774028 | Pegaspargase Combined With Gemcitabine, Etoposide, Liposomal Mitoxantrone Hydrochloride and Dexamethasone (P-GEMD) in the Treatment of Untreated Early Non-upper Respiratory Tract or Advanced Extranodal NK/T-cell Lymphoma | unknown | Phase 2 | 50 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | Mar 17, 2023 | clinicaltrials |
| NCT05772728 | Chidamide Combined With Azacitidine and Mitoxantrone Liposome in the Treatment of Relapsed/Refractory (nTFHL) | unknown | N/A | 23 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | Mar 16, 2023 | clinicaltrials |
| NCT00644189 | Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 50 | Massachusetts General HospitalOTHER | 1 | Mar 15, 2023 | clinicaltrials |
| NCT04602065 | Evaluation of Safety and Efficacy of IBI318 Monotherapy for Relapsed/Refractory Extranodal NK/T Cell Lymphoma (Nasal Type) Trial | terminated | Phase 1 / Phase 2 | 9 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Mar 15, 2023 | clinicaltrials |
| NCT02419287 | Pilot Study of Crizotinib in Relapsed ALK+ Lymphomas | completed | Phase 2 | 12 | University of Milano BicoccaOTHER | 1 | Mar 6, 2023 | clinicaltrials |
| NCT05513612 | Novel CAR-T Cell Therapy in the Treatment of Hematopoietic and Lymphoid Malignancies | withdrawn | Phase 1 | 0 | Shanghai Pudong HospitalOTHER | 1 | Mar 1, 2023 | clinicaltrials |
| NCT04021082 | CELTIC-1: A Phase 2B Study of Cerdulatinib in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL) | withdrawn | Phase 2 / Phase 3 | 0 | Portola PharmaceuticalsINDUSTRY | 0 | Feb 21, 2023 | clinicaltrials |
| NCT00585195 | A Study Of Oral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer(PROFILE 1001) | completed | Phase 1 | 596 | PfizerINDUSTRY | 4 | Feb 8, 2023 | clinicaltrials |
| NCT04334174 | Study of Brentuximab Vedotin as Therapy After Autologous Stem Cell Transplant in Cluster of Differentiation Antigen 30 (CD30) Positive Peripheral TCell Lymphomas(BRENTICON-T) | withdrawn | Phase 2 | 0 | University of Kansas Medical CenterOTHER | 1 | Feb 3, 2023 | clinicaltrials |
| NCT05526638 | Serum and Tissue Level of Interleukin-15 (IL-15) and IL-15 Receptor Alpha (IL-15Rα) in Mycosis Fungoides | unknown | N/A | 15 | Cairo UniversityOTHER | 1 | Feb 2, 2023 | clinicaltrials |
| NCT01746173 | CHOEP + High Dose Therapy + Auto SCT for T-Cell Lymphoma | terminated | Phase 2 | 5 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 30, 2023 | clinicaltrials |
| NCT02314247 | Efficacy and Safety Study of Selinexor in Relapsed or Refractory Peripheral T-cell Lymphoma or Cutaneous T-cell Lymphoma | terminated | Phase 2 | 16 | Karyopharm Therapeutics IncINDUSTRY | 2 | Jan 26, 2023 | clinicaltrials |
| NCT05303480 | Deep Phenotyping of Cutaneous T Cell Lymphoma, Type Mycosis Fungoides | completed | N/A | 32 | Centre for Human Drug Research, NetherlandsOTHER | 1 | Jan 25, 2023 | clinicaltrials |
| NCT01028716 | Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies | terminated | Phase 2 | 46 | Fred Hutchinson Cancer CenterOTHER | 1 | Jan 23, 2023 | clinicaltrials |
| NCT05017337 | Breast-implant ASsocIated anaplastIc Large Cell Lymphoma and CApsular Contracture(BASILICA) | unknown | — | 100 | Royal Marsden NHS Foundation TrustOTHER | 1 | Jan 19, 2023 | clinicaltrials |
| NCT03049449 | T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas | completed | Phase 1 | 26 | National Cancer Institute (NCI)NIH | 1 | Jan 18, 2023 | clinicaltrials |
| NCT03109353 | Modification of Extracorporeal Photopheresis in Cutaneous T-cell Lymphoma or Chronic Graft-versus-host Disease | completed | Phase 1 / Phase 2 | 7 | St. Olavs HospitalOTHER | 1 | Jan 13, 2023 | clinicaltrials |
| NCT01712659 | Ruxolitinib for Adult T-Cell Leukemia | terminated | Phase 1 / Phase 2 | 19 | National Cancer Institute (NCI)NIH | 1 | Jan 10, 2023 | clinicaltrials |
| NCT01796002 | Efficacy and Safety of Romidepsin CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma | completed | Phase 3 | 421 | The Lymphoma Academic Research OrganisationOTHER | 8 | Jan 10, 2023 | clinicaltrials |
| NCT03281811 | Photodynamic Therapy in Treating Patients With Refractory Mycosis Fungoides | completed | Early Phase 1 | 11 | Mayo ClinicOTHER | 1 | Jan 5, 2023 | clinicaltrials |
| NCT04185220 | Phase I Study of Recombinant Human IL-15 (rhIL-15) and Mogamulizumab for People With Refractory or Relapsed Adult T-Cell Leukemia and Mycosis Fungoides/Sezary Syndrome | completed | Phase 1 | 6 | National Cancer Institute (NCI)NIH | 1 | Jan 4, 2023 | clinicaltrials |
| NCT03775525 | Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or in Combination With Capecitabine in Metastatic Hormone Receptor Positive Breast Cancer(GEN602) | unknown | Phase 1 | 127 | Genzada Pharmaceuticals USA, Inc.INDUSTRY | 1 | Dec 23, 2022 | clinicaltrials |
| NCT03873493 | A Study Evaluating the Efficacy of Venetoclax Plus Ibrutinib in Participants With T-cell Prolymphocytic Leukemia | completed | Phase 2 | 14 | AbbVieINDUSTRY | 9 | Dec 19, 2022 | clinicaltrials |
| NCT02643303 | A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers | completed | Phase 1 / Phase 2 | 58 | Ludwig Institute for Cancer ResearchOTHER | 1 | Dec 2, 2022 | clinicaltrials |
| NCT04860817 | A Study of Anti-CD7 CAR-T Cells in Pediatric and Young Adult Patients With Relapse and Refractory T-ALL/ T-LBL | withdrawn | Early Phase 1 | 0 | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of ChinaOTHER | 1 | Nov 29, 2022 | clinicaltrials |
| NCT05620680 | CD7 CAR-T Cells in T-cell Lymphoma/Leukemia | recruiting | N/A | 20 | Shenzhen University General HospitalOTHER | 1 | Nov 17, 2022 | clinicaltrials |
| NCT05559008 | A Umbrella Study in R/R PTCL Guided by Molecular Subtypes | unknown | Phase 1 / Phase 2 | 116 | Ruijin HospitalOTHER | 1 | Nov 9, 2022 | clinicaltrials |
| NCT04922567 | Efficacy and Safety of Lenalidomide Plus CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma | recruiting | Phase 2 | 289 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Nov 7, 2022 | clinicaltrials |
| NCT04639843 | Doxorubicin, CC-(486) (5-azacitidine), Romidepsin, and Duvelisib (hARD) for T-cell Lymphoma | withdrawn | Phase 1 | 0 | National Cancer Institute (NCI)NIH | 1 | Nov 4, 2022 | clinicaltrials |
| NCT02811783 | Naloxone Hydrochloride Study for Relief of Pruritus in Patients With MF or SS Forms of CTCL | terminated | Phase 3 | 59 | Elorac, Inc.INDUSTRY | 1 | Oct 28, 2022 | clinicaltrials |
| NCT03770000 | Safety and Efficacy of Tenalisib (RP6530) in Combination With Romidepsin in Patients With Relapsed/Refractory T-cell Lymphoma | completed | Phase 1 / Phase 2 | 33 | Rhizen Pharmaceuticals SAINDUSTRY | 1 | Oct 28, 2022 | clinicaltrials |
| NCT05596266 | CD5 CAR-T Therapy for Refractory/Relapsed CD5+ T-cell Acute Lymphoblastic Leukemia | unknown | Phase 1 | 20 | Xuanwu Hospital, BeijingOTHER | 1 | Oct 27, 2022 | clinicaltrials |
| NCT04444141 | A Study of PD-1/CTLA-4 Bispecific AK104 in Relapsed or Refractory Peripheral T-cell Lymphoma | terminated | Phase 1 / Phase 2 | 6 | AkesoINDUSTRY | 1 | Oct 19, 2022 | clinicaltrials |
| NCT05239910 | Study to Evaluate the Efficacy and Safety of Tenalisib, Given With CHOP Therapy for Front Line Treatment in Patients With PTCL | withdrawn | Phase 2 | 0 | Rhizen Pharmaceuticals SAINDUSTRY | 1 | Oct 17, 2022 | clinicaltrials |
| NCT04118868 | Pembrolizumab Administered Via the Sofusa® DoseConnect™ in Patients With Relapsed/Refractory Cutaneous T-cell Lymphoma. | unknown | Phase 1 | 10 | Sorrento Therapeutics, Inc.INDUSTRY | 1 | Oct 12, 2022 | clinicaltrials |
| NCT05569057 | A Phase I Trial of SIM1811-03 in Subjects With Advanced Solid Tumors and Cutaneous T-cell Lymphoma | unknown | Phase 1 | 100 | Jiangsu Simcere Pharmaceutical Co., Ltd.INDUSTRY | 1 | Oct 7, 2022 | clinicaltrials |
| NCT05367856 | Efficacy and Safety of Chidamide Combined With BEAM Pretreatment Regimen in Autologous Transplantation for T-cell Lymphoma | unknown | Phase 2 | 23 | Ruijin HospitalOTHER | 1 | Sep 29, 2022 | clinicaltrials |
| NCT05557903 | Phase Ⅰ Clinical Study of Anti-CD52 Monoclonal Antibody in NHL and T-PLL | unknown | Phase 1 | 71 | Lanzhou Institute of Biological Products Co., LtdINDUSTRY | 1 | Sep 28, 2022 | clinicaltrials |
| NCT02572453 | Phase 2 Study of AT13387 (Onalespib) in ALK+ ALCL, MCL, and BCL-6+ DLBCL | terminated | Phase 2 | 25 | National Cancer Institute (NCI)NIH | 1 | Sep 13, 2022 | clinicaltrials |
| NCT03905135 | Interleukin-15 (IL-5) in Combination With Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell Malignancies | completed | Phase 1 | 8 | National Cancer Institute (NCI)NIH | 1 | Sep 13, 2022 | clinicaltrials |
| NCT05156229 | A Phase 1/2a Study of CDK-003 in Patients With Cutaneous T-Cell Lymphoma (CTCL).(Part B) | terminated | Phase 1 | 2 | Codiak BioSciencesINDUSTRY | 1 | Sep 2, 2022 | clinicaltrials |
| NCT00684619 | 506U78 In Relapsed Or Refractory Acute Lymphoblastic Leukemia (T-ALL) | completed | Phase 2 | 120 | Goethe UniversityOTHER | 1 | Aug 18, 2022 | clinicaltrials |
| NCT02859402 | Allogeneic Stem Cell Transplantation in Relapsed/Refractory T-, NK/T-cell Lymphomas(RRTCLAlloSCT) | recruiting | Phase 2 | 34 | Keimyung University Dongsan Medical CenterOTHER | 1 | Aug 18, 2022 | clinicaltrials |
Data updated 24 days agoSource updated Apr 27, 2023source: clinicaltrials